Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

NCT07340541 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

700

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer
Estrogen-receptor-positive Breast Cancer
Hormone Receptor Negative Breast Carcinoma

Interventions

DRUG: SERD* + abemaciclib
DRUG: SERD* + everolimus
DRUG: SERD* + everolimus or capecitabine
DRUG: SOC
DRUG: Antiandrogen

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]